What is the significance of onconeural antibodies for psychiatric symptomatology? A systematic review by Sæther, Sverre Georg et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
What is the significance of onconeural antibodies for psychiatric symptomatology? A
systematic review
Sæther, Sverre Georg; Schou, Morten; Kondziella, Daniel
Published in:
BMC Psychiatry
DOI:
10.1186/s12888-017-1325-z
Publication date:
2017
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY
Citation for published version (APA):
Sæther, S. G., Schou, M., & Kondziella, D. (2017). What is the significance of onconeural antibodies for
psychiatric symptomatology? A systematic review. BMC Psychiatry, 17, [161]. https://doi.org/10.1186/s12888-
017-1325-z
Download date: 03. Feb. 2020
RESEARCH ARTICLE Open Access
What is the significance of onconeural
antibodies for psychiatric symptomatology?
A systematic review
Sverre Georg Sæther1,2*, Morten Schou1,2 and Daniel Kondziella2,3
Abstract
Background: Patients with intracellular onconeural antibodies may present with neuro-psychiatric syndromes. We
aimed to evaluate the evidence for an association between well-characterized onconeural antibodies and psychiatric
symptoms in patients with and without paraneoplastic central nervous system syndromes.
Methods: Eligible studies were selected from 1980 until February 2017 according to standardized review criteria and
evaluated using Quality Assessment of Diagnostic Accuracy Studies−2 (QUADAS-2). We included studies describing the
psychiatric symptomatology of onconeural antibody positive patients and the prevalence of onconeural antibodies in
patients with psychiatric disorders.
Results: Twenty-seven studies met the inclusion criteria. Six studies reported on the prevalence of well-characterized
onconeural antibodies in patients with different psychiatric disorders, ranging from 0% to 4.9%. Antibody prevalence in
controls was available from three studies, ranging from 0% to 2.8%. Data heterogeneity precluded a meta-analysis. Two
cerebrospinal fluid studies found well-characterized onconeural antibodies in 3.5% and 0% of patients with psychotic
and depressive syndromes, respectively.
Conclusions: The available evidence suggests that the prevalence of well-characterized onconeural antibodies in patients
with psychiatric disorders is generally low. However, the question whether onconeural antibodies are important in select
patients with a purely psychiatric phenotype needs to be addressed by appropriately designed studies in the future.
Keywords: Paraneoplastic neuro-psychiatric syndromes, Onconeural antibodies, Anti-neuronal antibodies, Review
Background
Paraneoplastic central nervous system (CNS) syndromes
can be defined as remote effects of cancer on the brain
that are not caused by tumor infiltration, metastases,
metabolic or nutritional deficits, secondary infections or
oncological treatment [1]. These syndromes are strongly
associated to well-characterized onconeural antibodies
and present with psychiatric and/or neurological symp-
toms [2–4]. For instance, paraneoplastic limbic enceph-
alitis typically evolves over days to weeks and includes
memory disturbances and seizures, as well as psychiatric
symptoms such as irritability, hallucinations, depression,
and disturbances of mood and personality [2, 5]. Onco-
neural antibodies target intracellular antigens in tumors
and neuroectodermal tissues and are associated with
various types of cancer and clinical syndromes (See
Table 1 for details) [6, 7]. Well-characterized onconeural
antibodies include anti-Hu (ANNA-1), -Ri (ANNA-2),
-Yo, -CRMP5 (CV2), -Ma1, -Ma2 (Ta), -Amphiphysin,
-Recoverin, -Tr and -SOX1 [7, 8]. In contrast to the
well-documented pathogenicity of antibodies targeting
neuronal surface antigens (e.g. anti-NMDAR), it is as-
sumed that onconeural antibodies represent an epiphe-
nomenon to cytotoxic T-cell reactions [9, 10]. There is,
however, some evidence for their direct pathogenicity. For
instance, one group of researchers recently found anti-Yo
to cause dysregulation of the calcium homeostasis in Pur-
kinje cells in rat cerebellar slice cultures [11]. A different
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research group demonstrated that anti-Hu and anti-Yo in-
duce neuronal and Purkinje cell death, respectively, in hip-
pocampal and cerebellar slice cultures from rats [12–14].
The psychiatric literature on onconeural antibodies and
paraneoplastic neurological syndromes is sparse [15].
Some authors have suggested that onconeural antibodies
may play a role as a marker of autoimmune processes in
subgroups of patients with psychiatric disorders [16, 17].
If this is true, onconeural antibody status might have im-
plications for choice of therapeutic strategy and possibly
also indicate the need for tumor screening in serum
positive patients. On the other hand, if the hypothesis is
false, onconeural antibody testing may be unnecessary.
We aimed to determine the evidence for an association
of onconeural antibodies with the occurrence, persistence
or worsening of psychiatric symptoms in patients with
(and without) paraneoplastic CNS disease. Using the
PICO approach [18], we phrased the following primary re-
search question: In patients with psychiatric symptoms
(Population), does a positive onconeural antibody test re-
sult (Intervention) compared to a negative test result
(Comparison) predict a different psychopathological pro-
file, i.e. greater burden of affective, cognitive and/or psych-
otic symptoms (Outcome)? For secondary outcomes: Do
patients with 1) malignancies or 2) paraneoplastic syn-
dromes (P) and a positive onconeural antibody test result
(I), as compared to those with a negative test result (C),
present with a different psychopathological profile (O)?
Methods
We performed a systematic review using standardized
methods (Quality Assessment of Diagnostic Accuracy
Studies-2 (QUADAS-2) and Preferred Reporting Items for
Systematic Reviews and Meta-analyses (PRISMA) [19,
20]). The review protocol was registered in the PROS-
PERO database (registration number CRD42015025826)
and can also be accessed from Additional file 1.
Criteria for considering studies for this review
Types of studies
The criteria for inclusion and exclusion of studies are
presented in Table 2.
Index test and reference standards
The index test comprised onconeural antibodies in patient
serum or cerebrospinal fluid. We addressed the following
well-characterized onconeural antibodies: anti-Hu (ANNA-
1), -Ri (ANNA-2), -Yo, -CRMP5 (CV2), -Ma1, -Ma2 (Ta),
-Amphiphysin, -Recoverin, -Tr and -SOX1. Established clin-
ical criteria for malignancies, paraneoplastic neurological
syndromes and psychiatric disorders according to standard
clinical criteria, e.g. ICD-10, DSM-III-R, DSM-IV and DSM-
IV-TR were considered as reference standards [21–24].
Search methods for identification of studies
We searched the following databases for relevant litera-
ture from 1 January 1980 to 15 February 2017: Cochrane
Central Register of Controlled Trials (The Cochrane
Library), Medline (PubMed), EMBASE, and clinical-
trials.gov. The search was based on the following terms:
Paraneoplastic syndromes, onconeural antibodies, psych-
iatry, mental disorders, depression, psychosis, neo-
plasms, cancer, antibodies. See Additional file 1 for
details. An academic librarian supervised the literature
search. We manually searched the references from rele-
vant manuscripts to identify additional articles. Further,
we cross-referenced the papers using the “cited by” func-
tion on PubMed. Non-English literature were included if
an English Abstract was available and a reliable transla-
tion of the manuscript into English possible. If necessary,
Table 1 Well-characterized onconeural antibodies and their
associated tumors and syndromes (Modified after [7])
Onconeural
antibody
Tumorsa CNS syndromesa
Hu (ANNA-1) SCLC, other lung ca.,
prostate ca.
PCD, LE, PEM, OMS,
BE, myelitis
Ri (ANNA-2) Mamma ca., SCLC,
other lung ca.
BE, OMS, PCD, LE,
PEM, myelitis
Yo (PCA-1) Ovary ca., uterus ca.,
mamma ca.
PCD
CRMP-5 (CV2) SCLC, other lung ca.,
thymoma
PCD, LE, PEM, BE,
myelitis
Ma1 Lung ca., mamma ca.,
colon ca.
BE, PCD, PEM, LE,
OMS
Ma2 (Ta) Testis ca. LE, PCD, Dienc. and
brainstem symptoms
Amphiphysin Mamma ca., SCLC,
colon ca.
SPS, PEM, PCD, LE
Recoverin SCLC, other lung ca.,
mamma ca.
Retinopathy
Tr Lymphoma PCD
SOX1 SCLC LE, PCD, BE
aOnly most frequent tumors and syndromes described. Abbreviations: BE
Brainstem encephalitis, ca cancer CNS Central nervous system, Dienc
Diencephalic, LE Limbic encephalitis, OMS Opsoclonus-myoclonus-syndrome,
PCD Paraneoplastic cerebellar degeneration, PEM Paraneoplastic encephalomy-
elitis, SCLC Small cell lung cancer, SPS Stiff-person-syndrome
Table 2 Inclusion and exclusion criteria for the systematic review
Inclusion criteria Aims:
* Prevalence of well-characterized onconeural
antibodies in patients with psychiatric disorders
* Psychiatric symptomatology of onconeural
antibody positive patients in patients with
psychiatric disorders, malignancies and/or
paraneoplastic neurological syndromes
Design: Retrospective, prospective, observational
and/or interventional
Exclusion criteria Study sample < 5 patients
Pediatric or adolescent patients (age < 18)
Non-validated methods for onconeural antibody
testing
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personal communication with authors was attempted via
email in order to obtain additional data.
Data collection, analysis, and reporting
Selection of studies, data extraction, and management
In papers with relevant titles, abstracts were evaluated.
Eligible studies were then identified on the basis of their
full text. One author (SGS) performed the initial selec-
tion, whereas two authors (SGS and MBS) performed a
quality assessment. One of the authors (SGS) extracted
the relevant information from each study, which was
validated by a second author (MBS).
Assessment of methodological quality, including
investigations of heterogeneity
Two of the authors (SGS and MBS) independently
assessed the methodological quality of each included
study using the Quality Assessment of Diagnostic Accur-
acy Studies-2 (QUADAS-2) [19]. The QUADAS-2 has
four domains: (1) participant selection, (2) index test, (3)
reference standard, and (4) flow of participants through
the study and timing of the index tests and reference
standard (flow and timing). Risk of bias is judged as
“low”, “high” or “unclear” for each domain. The first
three domains are also assessed for concerns regarding
applicability. A third author (DK) resolved disagreement
if consensus could not be reached by the two reviewing
authors.
Statistical analysis, data synthesis, and reporting
We aimed to perform a meta-analysis of the available
numerical data reporting on 1) the frequency of onco-
neural antibodies in patients with psychiatric symptoms
and/or diagnoses, 2) the frequency of psychiatric symp-
toms in patients with onconeural antibodies, and 3) the
psychopathological profile of patients with onconeural
antibodies. However, a meta-analysis was judged as mea-
ningful only if design and quality of the included studies
were deemed satisfactory. Data were reported according
to the PRISMA criteria [20] (Additional file 1).
Results
Results are summarized in Tables 3 and 4 and Fig. 2.
Systematic literature search and quality assessment
The initial search yielded 6069 citations (Se Fig. 1 for
Flow chart). We identified 27 original publications that
met eligibility criteria [2, 17, 25–49]. Data about the
serum prevalence of well-characterized onconeural anti-
bodies in patients with psychiatric disorders were avail-
able from 6 papers [17, 29, 41, 43, 44, 46]. Authors of 1
paper reported on the prevalence of anti-Purkinje cell
antibodies “similar to those found in paraneoplastic
cerebellar degeneration”, but did not specify if tests for
well-characterized onconeural antibodies were performed
[39]. Two studies investigated the prevalence of well-
characterized onconeural antibodies in the CSF of patients
with psychotic and depressive syndromes [42, 45]. Thir-
teen papers included data on clinical characteristics of
patients with a particular paraneoplastic neurological syn-
drome and/or positive onconeural antibody test result
[25–28, 30–32, 35–38, 47, 49]. The authors of 4 studies
reported on clinical characteristics of autoimmune and
paraneoplastic limbic encephalitis in general, including
cases associated with onconeural antibodies [2, 34, 40, 48].
Using the QUADAS-2, we found that 18 of 27 studies had
a high applicability concern regarding patient selection
(see Table 3 and Fig. 2) [2, 25–28, 30–38, 40, 47–49].
These studies did not evaluate patients with psychiatric
symptoms (our primary review question) but with
paraneoplastic neurological syndromes or malignan-
cies (secondary review questions). In addition, the
same studies lacked a reference standard regarding
psychiatric symptoms. This explains the high applic-
ability concern and risk of bias for reference stan-
dards in these 18 studies (Table 3).
Patient population
The 27 studies included in the review had heterogeneous
patient populations (total n = 3820). Nine studies included
patients with psychiatric disorders (total n = 3066) [17, 29,
39, 41–46]. The remaining studies described symptoms
from patients with a particular paraneoplastic neurological
syndrome and/or positivity to a particular onconeural
antibody (n = 555) [25–28, 30–33, 35–38, 47, 49], or
autoimmune/limbic encephalitis (n = 199) [2, 34, 40, 48].
Due to the heterogeneity in patient populations (Table 4)
a meta-analysis was considered inappropriate.
Onconeural antibody testing
The majority of studies employed immunoblot or
western blot techniques as the reference standard for de-
tecting onconeuronal antibodies [2, 17, 26–28, 30–37,
40, 42–47], often in combination with indirect immuno-
flourocence (IIF) or immunhistochemistry [2, 17, 26–28,
30–34, 37, 40, 43, 44, 46, 48, 49]. When immunoblot/
western blot was not used, IIF was performed [25, 29,
38, 39, 41]. There was a large variability in the specific
antibodies analyzed and number of antibodies analyzed
in each study. Authors from 2 studies did not use
specific antibody testing but analyzed Purkinje cell
antibodies in general [25, 39].
Reference standard
Six studies used a validated reference standard for judg-
ment of psychiatric disorders (ICD-10, DSM-III-R or
DSM-IV) [17, 29, 39, 41, 43, 46]. Three other studies also
included patients with psychiatric disorders [42, 44, 45].
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These studies were conducted in secondary or tertiary
psychiatric departments and it is thus likely that a board-
certified psychiatrist evaluated the patients although this
was not clearly stated. However, the studies were judged
to have an unclear bias and applicability concern due to
lack of information on the reference standard used. Han-
sen et al. screened for depressive symptoms using BDI
(Becks Depression Inventory) and review of patient charts,
but did not assess other psychiatric symptoms [48]. The
remaining 17 studies did not have a reference standard for
the evaluation of psychiatric symptoms. These studies
were not designed to screen for psychiatric symptoms
and/or disorders [2, 25–28, 30–38, 40, 47, 49].
Serum prevalence studies
Six studies reported on the prevalence of 3 or more well-
characterized onconeural antibodies in patients with
psychiatric disorders [17, 29, 41, 43, 44, 46]. Dahm et al.
screened patients with schizophrenia (n = 1378), affective
disorders (n = 310), borderline personality disorders
(n = 42) and healthy blood donors (n = 1703) for the pres-
ence of a wide range of onconeural antibodies (all as listed
in this review protocol, except anti-SOX1). There were no
differences in prevalence of any of the onconeural anti-
bodies in healthy individuals and in patients from any of
the diagnostic groups [41]. Sæther et al. screened 585 pa-
tients admitted to acute psychiatric inpatient care for the
presence of all antibodies in this review protocol, except
anti-Ma1 [46]. Only 1 patient tested positive (anti-reco-
verin). Kruse et al. examined serum from 213 and CSF
from 10 psychiatric inpatients for a broad spectrum of
antibodies including anti-Hu, -Ri, -Tr, -SOX1, -Yo,
-CRMP-5 and -Amphiphysin [44]. One patient suffering
from frontotemporal dementia tested positive to anti-
Table 3 Systematic evaluation of publications included in the review using Quality Assessment of Diagnostic Accuracy Studies-2 [19]
Study Risk Of Bias Applicability Concerns
Patient
selection
Index
test
Reference
standard
Flow and
timing
Patient
selection
Index
test
Reference
standard
Hammack et al. 1990 [25] Unclear Low High High High High High
Dalmau et al. 1992 [26] Low Low High High High Low High
Peterson et al. 1992 [27] Low Low High High High Low High
Alamowitch et al. 1997 [28] Low Low High High High Low High
Black et al. 1998 [29] Unclear Low Low Low Low Low Low
Voltz et al. 1999 [31] Low Low High High High Low High
Antoine et al. 1999 [30] Low Low High High High Low High
Gultekin et al. 2000 [2] Unclear Low High High High Low High
Yu et al. 2001 [32] Low Low High High High Low High
Sillevis Smitt et al. 2002 [33] Low Low High High High Low High
Lawn et al. 2003 [34] High Low High High High Low High
Overeem et al. 2004 [36] High Low High High High Low High
Dalmau et al. 2004 [35] Low Low High High High Low High
Hoffmann et al. 2008 [37] Unclear Low High High High Low High
McKeon et al. 2011 [38] Low Low High High High Low High
Chiaie et al. 2012 [39] High Low Low Low Low High Low
Saraya et al. 2013 [40] Low Low High High High Low High
Dahm et al. 2014 [41] Unclear Low Low Low Low Low Low
Moon et al. 2014 [47] Low Low High High High Low High
Laadhar et al. 2015 [17] Low Low Low Low Low Low Low
Haukanes et al. 2015 [43] High Low Low Low Low Low Low
Kruse et al. 2015 [44] High Low Unclear Low Low Low Unclear
Endres et al. 2015 [42] High Low Unclear Low Low Low Unclear
Sæther et al. 2016 [46] Low Low Low Low Low Low Low
Endres et al. 2016 [45] High Low Unclear Low Low Low Unclear
Hansen et al. 2016 [48] High Low High High High Low High
Schwenkenbecher et al. 2016 [49] Low Low High High High Low High
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CRMP-5. The remaining 212 patients and 173 healthy
controls tested negative to all the above-mentioned anti-
bodies. Haukanes et al. screened 169 adult ADHD patients
for the presence of anti-Yo, -Hu, -Ri, -Ma2, -CRMP-5 and
-Amphiphysin [43]. While 10 of the patients had antibodies
targeting Purkinje cells, none tested positive to well-
characterized onconeural antibodies. Black et al. did not
find anti-Yo, -Hu, -Ri or -Amphiphysin among 13 patients
diagnosed with obsessive-compulsive disorder [29]. Laadhar
et al. reported unspecified antineuronal nuclear autoanti-
bodies (ANNA) in 20/103 patients with schizophrenia,
schizoaffective and bipolar disorder compared to 0/41
healthy controls. However, only 2 of them had well-
characterized onconeural antibodies (anti-Ri). Further
Fig. 1 Schematic overview of the literature research
Fig. 2 Systematic evaluation of bias and applicability concern in studies included in the review using QUADAS-2 [19]
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they reported antibodies directed to the cytoplasm of
Purkinje cells in 6/103 patients and 2/41 controls.
Three of the patients and none of the controls were
positive to a well-characterized onconeural antibody
(anti-Yo) [17]. Laadhar et al. only performed tests for
3 well-characterized onconeural antibodies (Anti-Hu,
anti-Ri, and anti-Yo).
Another prevalence study screened 48 patients with
psychiatric disorders (24 schizophrenia, 17 bipolar dis-
order and 7 obsessive-compulsive disorder) and 52
healthy controls for anti-Purkinje cell antibodies “similar
to those found in paraneoplastic cerebellar degener-
ation”. It was not reported whether tests for well-
characterized onconeural antibodies associated with
paraneoplastic cerebellar degeneration (i.e. anti-Yo) were
performed. Eleven of 48 psychiatric patients had anti-
Purkinje antibodies compared to none of the controls
[39]. In this study, Purkinje cell antibodies were associ-
ated with acute clinical presentations and positive psy-
chopathological symptoms (hallucinations, delusions,
bizarre behavior and thought disturbances) [39]. How-
ever, according to the QUADAS-2, applicability concerns
regarding the index test in this study were high because
information on specific testing for well-characterized
onconeural antibodies was lacking.
Cerebrospinal fluid studies in patients with psychiatric
disorders
Endres et al. reported on the prevalence of intracellular
onconeural antibodies in the cerebrospinal fluid (CSF) of
patients with psychotic and depressive syndromes [42, 45].
Among 180 patients with psychotic syndromes, CSF from
142 patients were screened for the presence of anti-Yo,
-Hu, -Ri, -CRMP-5/CV2, -Ma1, -Ma2, -SOX1 and
-Amphiphysin [42]. Three patients tested positive to anti-
Yo, 1 to anti-Hu and 1 to anti-CRMP-5/CV2. All these pa-
tients had schizophreniform or schizoaffective syndromes.
Examining patients with depressive syndromes, the same
authors found CSF from 63 patients to be negative for the
above-mentioned intracellular antibodies [45]. None of
the CSF studies included a control group.
Studies on autoimmune encephalitis
In a study on 103 patients with encephalitis of possibly
autoimmune origin, 9 patients tested positive for a
well-characterized onconeural antibody (7 anti-Ri, 2
anti-Yo) [40]. Of these, 2 anti-Ri positive patients pre-
sented with the combination of psychosis and seizures,
whereas 1 anti-Yo positive patients presented with be-
havioral changes. In another study, 30 of 50 patients
with paraneoplastic limbic encephalitis tested positive
to well-characterized onconeural antibodies (18 anti-
Hu, 10 anti-Ma1/Ma2, 2 anti-Ma1) [2]. Psychiatric
symptoms were present in 21/50 patients and included
hallucinations and changes in affect and personality.
The prevalence of psychiatric symptoms in patients
testing positive to anti-Hu (5/18) or anti-Ma1/Ma2 (6/
10) was not different from that in other patients (10/
22). Yet another study investigated the clinical, mag-
netic resonance imaging and electroencephalographic
findings in 24 patients with paraneoplastic limbic
encephalitis [34]. The authors reported well-
characterized onconeural antibodies in 10 patients (6
anti-CRMP5 and 4 anti-Hu). All patients tested nega-
tive for anti-Ri, anti-Yo and anti-Tr. Psychiatric symp-
toms were noted in 12 of the 24 patients with
paraneoplastic limbic encephalitis, including depres-
sion, anxiety, personality changes and hallucinations.
Seven patients had psychiatric symptoms as their ini-
tial manifestation. Eight out of 10 patients with anti-
CRMP-5 or anti-Hu antibodies had clinical or radio-
logical evidence of extralimbic encephalitis involve-
ment compared to 4 out of 12 patients without these
antibodies (p = 0.04). However, the authors did neither
provide data on the degree of limbic involvement nor
of the psychiatric symptomatology in these two
groups. Hansen et al. aimed to assess the efficacy of
immunotherapy in patients with different types of limbic
encephalitis [48]. In their paper, they also provided clinical
characteristics of 11 patients with onconeural antibodies
(anti-Ma2, -Yo, -SOX1, -Recoverin or -Amphiphysin) and
compared them to that of 11 anti-GAD65 positive pa-
tients. The authors found that patients with onconeural
antibodies had a significantly greater improvement of de-
pression scores (Becks Depression Inventory) following
immunotherapy as compared to anti-GAD65-positive pa-
tients. Other psychiatric symptoms, however, were not
assessed.
Studies on individual onconeural antibodies
Anti-Hu was the subject of investigation in 4 papers.
Dalmau et al. presented a clinical study including 71 pa-
tients with anti-Hu associated paraneoplastic encephalo-
myelitis/sensory neuronopathy [26]. They described 15
patients (21%) presenting with limbic symptoms such as
confusion, depression, anxiety and memory loss. Six of
these patients presented with partial-complex seizures
that included gustatory, auditory, or olfactory hallucina-
tions. In another study 16 patients with limbic encephal-
itis and small cell lung cancer were included [28].
Psychiatric symptoms such as depression, anxiety, per-
sonality changes, and hallucinations were frequent in
both anti-Hu positive (7/8) and negative (7/8) patients.
Following neurological stabilization in 73 anti-Hu posi-
tive patients with paraneoplastic encephalomyelitis/sen-
sory neuronopathy, 2 patients were found to have
depressive symptoms [33]. Aiming to differentiate anti-
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Hu positive patients with peripheral neuropathy and en-
cephalitis by CSF parameters, the authors of another
paper noted that some of the patients with limbic involve-
ment presented with anxiety and aggressive behavior [49].
However, no systematic evaluation of psychiatric symp-
toms was performed.
Four papers described clinical symptoms associated
to anti-Ma1 and/or anti-Ma2. In the initial description
of the anti-Ma2 antibody, Voltz et al. referred to 10 pa-
tients with testicular cancer, paraneoplastic limbic or
brainstem encephalitis, and the presence of serum anti-
Ma2 antibodies [31]. To further assess the symptoms of
anti-Ma2-associated encephalitis, Dalmau et al. re-
ported a comprehensive clinical analysis of 38 patients,
including the 10 mentioned previously [35]. The pre-
senting features included psychiatric symptoms such as
“nervous breakdowns” (2 patients), loss of self-
confidence (1 patient) and panic attacks (1 patient). In
another study of 22 cases of anti-Ma1/Ma2 associated
paraneoplastic neurological syndromes, 2 patients pre-
sented with psychiatric symptoms (personality change,
obsessive compulsive symptoms) [37]. Investigating
hypocretin-1 CSF levels in patients with anti-Ma2 asso-
ciated encephalitis; Overeem et al. reported that 3 out
of 6 patients had psychiatric symptoms (depression,
personality changes) [36]. However, these patients also
developed neurological symptoms such as seizures and
diplopia.
Anti-Yo associated paraneoplastic neurological syn-
dromes often present with cerebellar ataxia. In a clinical
analysis by Peterson et al. of 55 patients with anti-Yo
antibodies and paraneoplastic cerebellar degeneration 10
patients had cognitive impairment, including emotional
lability and memory deficits [27]. Other psychiatric
symptoms were not recorded. McKeon et al. described
the clinical profiles of 83 patients testing positive to
anti-Yo at the Mayo Clinic during a 21-year period.
From clinical records, they noted personality changes in
4 patients [38]. Hammack et al. compared patients with
paraneoplastic cerebellar degeneration with Purkinje cell
antibodies with patients without. The authors did not
state if tests for well-characterized onconeural antibodies
associated to paraneoplastic cerebellar degeneration (i.e.
anti-Yo) were performed. Thus, this study was subject to
significant applicability concerns regarding the index
tests. The authors reported that mental status was ab-
normal more frequently in antibody positive (10/16)
than in antibody negative patients (5/16). Depression or
psychosis were present in 6 of 16 seropositive patients
compared to 3 of 16 seronegative patients, whereas the
remaining patients with altered mental status had de-
mentia or delirium [25].
In 116 patients with CRMP-5/CV2 antibodies, psychi-
atric abnormalities were reported in 24 patients (11
personality changes, 9 depression, 4 psychosis) [32]. It
is unclear how many of these patients had co-occurring
neurological symptoms, however.
Two papers focusing on anti-amphiphysin met the
inclusion criteria. One of them reported five cases of
anti-amphiphysin associated paraneoplastic neuro-
logical syndromes [30]. In 1 of these patients the initial
symptoms were anxiety and depression. Later, the pa-
tient’s neurological status deteriorated and he devel-
oped olfactory and auditory hallucinations. The authors
of another study described clinical manifestations and
immunotherapy response of patients with non-stiff
anti-amphiphysin syndrome [47]. Four out of 20 pa-
tients were described as irritable, but all of them had
co-existing symptoms such as cognitive impairment or
seizures. Another patient had been treated for psychotic
symptoms in a psychiatric department for 10 years be-
fore amphiphysin antibodies were discovered. This pa-
tient additionally suffered from seizures, cognitive
impairment, depressive symptoms and emotional labil-
ity. The authors noted that the psychiatric symptoms
improved following treatment with IVIG (intravenous
immunoglobulin) and oral Prednisolone.
Discussion
Our primary research question was whether onconeural
antibody status predicts the psychopathological profile
in patients with psychiatric symptoms. Based on the six
studies designed to answer this question [17, 29, 41, 43,
44, 46], it seems fair to conclude that the serum preva-
lence of well-characterized onconeural antibodies in pa-
tients with psychiatric disorders is generally low. Indeed,
the prevalence does not seem to be significantly different
from that in healthy controls. However, these studies in-
clude patients fulfilling the criteria for primary psychi-
atric disorders. It could be hypothesized that patients
with psychiatric symptoms admitted to medical or surgi-
cal facilities because of a co-occurring somatic disease
might have a higher prevalence.
CSF studies are rare in patients with psychiatric disor-
ders; hence, the data on antibody prevalence in CSF are
even more limited. Interestingly, Endres et al. found CSF
from five of 142 patients with psychotic syndromes to be
positive for anti-Yo, −Hu or -CRMP-5/CV2 [42].
To advance this field there is a need for collabor-
ation between psychiatrist and neuroimmunologists.
Future studies investigating the significance of onco-
neural antibodies for psychiatric symptomatology
should not only assess the prevalence of these anti-
bodies in psychiatric diagnostic categories. They
should also investigate associations to symptom sever-
ity (e.g. degree of hallucinations, delusions and de-
pression) and symptom domains not captured be the
classical disorders (e.g. agitation and symptom
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fluctuation). Further, longitudinal studies are needed
to establish whether a positive onconeural antibody
test result in patients with psychiatric symptoms is a
trait (stable over time) or state (associated with exac-
erbations of psychiatric symptoms).
One of our two secondary review questions was about
onconeural antibody status possibly predicting the psy-
chopathological profile in patients with malignancies.
Our literature search yielded no studies designed to
answer this question. The other secondary research
questions concerned the possibility that onconeural
antibody status might predict the psychopathological
profile in patients with paraneoplastic CNS syndromes.
Many of the included studies evaluated the clinical phe-
notypes of syndromes associated to a particular onco-
neural antibody. However, comparisons of symptoms in
patients with a given syndrome (e.g. limbic encephal-
itis) with and without onconeural antibodies were only
presented in three studies. Gultekin et al. compared
clinical characteristics in three groups of patients with
paraneoplastic limbic encephalitis (patients positive to
anti-Hu, anti-Ma2 and others) [2]. Similarly, Alamo-
witch et al. compared clinical characteristics of patients
with limbic encephalitis and small cell lung cancer with
and without anti-Hu antibodies [28]. Both studies re-
ported similar prevalence of psychiatric symptoms in
patients with and without onconeural antibodies. How-
ever, the studies were small and included only a few of
the relevant onconeural antibodies. Hansen et al. re-
ported depressive symptoms in 73% of LE patients with
onconeural antibodies as compared to 50% in LE pa-
tients with GAD65 antibodies [48]. Surprisingly, the au-
thors reported that the depression scores improved
significantly more in onconeural antibody positive pa-
tients as compared to the anti-GAD65 group following
immunotherapy.
Our review has a few limitations. Only six prevalence
studies of well-characterized onconeural antibodies in pa-
tients with psychiatric disorders were identified [17, 29, 41,
43, 44, 46]. These studies generally had low a low risk of
bias as assessed by QUADAS-2. However, the studies dif-
fered in inclusion criteria and setting, and some of them
did not include all antibodies described in the review proto-
col. The largest study used indirect immunofluorescence to
screen for onconeural antibodies [41], but did not perform
a second confirmatory test (e.g. immunoblot or ELISA)
which recommended in some guidelines [7]. Eighteen of
the studies designed to answer one of our secondary re-
search questions were subject to a high risk of bias regard-
ing the reference standard [2, 25–28, 30–38, 40, 47–49].
This was mainly due to the lack of a structured psychiatric
evaluation and of validated diagnostic tools. The same stud-
ies also had high applicability concerns with regards to pa-
tient selection and reference standards.
Conclusions
Although psychiatric symptoms do occur in patients
with malignancies and paraneoplastic CNS syndromes,
the few available studies suggest that well-characterized
onconeural antibodies are infrequent in patients with
psychiatric disorders per se.
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